Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease.
BACKGROUND Peripheral arterial occlusion disease ( PAOD ) is caused mainly by chronic inflammation and endothelium dysfunction , and is often treated with cilostazol . However , because this drug 's influence on atherogenic cytokines is still not well known , this study examined the effect of cilostazol on the serum levels of soluble CD40 lig and ( sCD40L ) , adiponectin and high-sensitivity C-reactive protein ( hs-CRP ) in patients with type 2 diabetes and PAOD . METHODS AND RESULTS The 92 type 2 diabetics with PAOD and 100 non-PAOD diabetics were enrolled and r and omly assigned to a group receiving either cilostazol or placebo for 6 months . The atherogenic cytokines were measured at the beginning and completion of the study . In the PAOD groups , those in the cilostazol group had significant changes in the levels of hs-CRP , sCD40L and adiponectin ( P=0.001 , P=0.05 , P=0.004 , respectively ) . Changes in the levels of adiponectin and sCD40L were more significant in the PAOD group treated with cilostazol than in the non-PAOD group also treated with the drug ( P=0.01 and P=0.008 , respectively ) . CONCLUSIONS Cilostazol can decrease hs-CPR and sCD40L levels and increase that of adiponectin , and then delay the progression of atherogenesis and chronic inflammation in type 2 diabetics , especially those with PAOD
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .